Search

Your search keyword '"DUAN, LIAN"' showing total 16 results
Start Over Author "DUAN, LIAN" Journal thoracic cancer
16 results on '"DUAN, LIAN"'

13. Management of immune checkpoint inhibitor‐related dermatologic adverse events.

Author

Si, Xiaoyan, He, Chunxia, Zhang, Li, Liu, Xiaowei, Li, Yue, Wang, Hanping, Guo, Xiaoxiao, Zhou, Jiaxin, Duan, Lian, and Wang, Mengzhao

Subjects
PREVENTION of drug side effects, SKIN disease prevention, SKIN disease treatment, DRUG interactions, EOSINOPHILIA, EXANTHEMA, ITCHING, TOXIC epidermal necrolysis, STEVENS-Johnson Syndrome, DISEASE risk factors
Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. The unique spectrum of immune‐related adverse events (IrAEs) may occur during treatment. Dermatologic toxicities appear to be one of the most prevalent immunotherapy‐related adverse events. The most common symptoms are maculopapular rash and pruritus. Serious dermatologic toxicities including Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reactions with eosinophilia and systemic symptoms are rare. In this review, we summarize guidelines of management of immunotherapy‐related toxicities, case reports, and proposed treatment recommendation. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

14. Clinical manifestation and management of immune checkpoint inhibitor‐associated cardiotoxicity.

Author

Guo, Xiaoxiao, Wang, Hanping, Zhou, Jiaxin, Li, Yue, Duan, Lian, Si, Xiaoyan, Zhang, Li, and Fang, Ligang

Subjects
IMMUNE checkpoint inhibitors, CARDIOTOXICITY, TUMORS
Abstract

Immune checkpoint inhibitors (ICIs) targeting programmed death‐1 (PD‐1), its ligand (PD‐L1), and cytotoxic T‐lymphocyte‐associated antigen 4 (CTLA4) have revolutionized cancer treatment by recovering the attack of T lymphocytes on the malignant cells. They have improved clinical outcomes dramatically in multiple types of advanced‐stage malignancies. Even though the tolerance and safety profiles are generally good, it has been widely reported that ICIs can cause severe or fatal immune‐related adverse events (irAEs), since the activated T lymphocytes are not specific for tumor cells. Cardiac irAEs appear to occur less frequently than irAEs in other organ systems but are notorious for high mortality. Here, we aim to identify and characterize the ICI‐associated cardiotoxicity and summarize the optional diagnosis and treatment strategies. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

15. Management of immune checkpoint inhibitor‐related rheumatic adverse events.

Author

Zhou, Jiaxin, Wang, Hanping, Guo, Xiaoxiao, Wang, Qian, Duan, Lian, Si, Xiaoyan, Zhang, Li, Liu, Xiaowei, Li, Yue, and Zhang, Wen

Subjects
IMMUNE checkpoint inhibitors, RHEUMATISM treatment, IMMUNOLOGICAL adjuvants, IMMUNOTHERAPY, RHEUMATISM, SYMPTOMS
Abstract

Immune checkpoint inhibitors (ICIs), which target the programmed cell death receptor‐1 and cytotoxic T lymphocyte‐associated antigen‐4 signaling pathways, represent remarkable breakthroughs in cancer treatment and have improved survival among patients with a variety of malignancies. However, the wide use of ICIs is associated with a spectrum of immune‐related adverse events (irAEs) that can affect any organ system, and may sometimes be life threatening. Rheumatic irAEs are not an infrequent type of irAE. In this systematic review, we consider the clinical characteristics of rheumatic irAEs, including patients with pre‐existing rheumatic diseases, and focus on the management of rheumatic irAEs. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

16. Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis.

Author

Wang, Hanping, Guo, Xiaoxiao, Zhou, Jiaxin, Li, Yue, Duan, Lian, Si, Xiaoyan, Zhang, Li, Liu, Xiaowei, Wang, Mengzhao, and Shi, Juhong

Subjects
LUNG disease diagnosis, LUNG disease treatment, IMMUNE system, IMMUNOTHERAPY, LUNG diseases, MONOCLONAL antibodies, T cells
Abstract

The increasing use of immune checkpoint inhibitors in tumors has brought new hope of survival to patients with advanced tumors. However, the immune system activated by immune checkpoint inhibitors, mainly activated T‐cells, can attack normal tissues and organs in the body and lead to a variety of adverse effects. In the lung, these attacks can induce checkpoint inhibitor pneumonitis (CIP). CIP is different from known pulmonary interstitial pneumonitis, and has the potential to be fatal if not treated correctly. In this review, we summarize the characteristics of CIP and provide advice on how to manage this disease. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results